Neuromed Initiates Pivotal Clinical Trial For Chronic Pain

Armen Hareyan's picture

Neuromed Pharmaceuticals has dosed its first patient in its pivotal Phase 3 clinical trial of NMED-1077 (OROS Hydromorphone) for the treatment of chronic moderate-to-severe pain.

"The options for strong once-daily pain relief medications in the U.S. for patients with chronic moderate-to-severe pain are limited and we believe NMED-1077 has the potential to address this unmet medical need," said Dr. Christopher Gallen, Neuromed's President & CEO. "The commencement of our pivotal Phase 3 trial of NMED-1077 is a significant milestone for Neuromed."

The design of the Phase 3 trial of NMED-1077 is a randomized withdrawal, placebo-controlled, double-blind trial which is being conducted at multiple centers in the U.S. The study will target enrollment of 272 patients and will evaluate the safety and efficacy of NMED-1077 in the treatment of chronic low back pain.


The pivotal Phase 3 clinical trial of NMED-1077 is being studied under an approved Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). A SPA is a procedure by which sponsors and the FDA reach agreement on the design and size of clinical trials intended to form the primary basis to support approval of a New Drug Application.

Neuromed acquired, from ALZA Corporation, the U.S. marketing rights to NMED-1077, an extended release formulation of hydromorphone. Hydromorphone is a Schedule II opioid that has been widely used for many years. Current formulations of hydromorphone marketed in the U.S. are immediate release, requiring dosing several times per day. NMED-1077 employs the OROS PUSH-PULL osmotic delivery system to release hydromorphone at a controlled rate over an extended period. OROS Hydromorphone has been approved in Germany and other European countries and is marketed by Janssen-Cilag under the name JURNISTA.

NMED-1077 is an investigational product and is not approved by the FDA for use in the U.S. NMED-1077 has been studied in more than 1,000 patients in analgesic trials. The most common adverse events seen in clinical trials to date are opioid-related events such as constipation, nausea, somnolence, headache, vomiting and dizziness. Respiratory depression is the most important hazard of opioid preparations including NMED-1077.

Neuromed is also evaluating two pathways for the development of new classes of oral pain drugs. In collaboration with Merck, Neuromed is researching compounds designed to block the N-type calcium channel, a target linked to pain signal transmission. Separately, Neuromed is also developing T-type calcium channel blockers aimed at treating acute and chronic pain as well as hypertension and epilepsy.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.